Work

Phase I lead-in to a 2x2x2 factorial trial of dose-dense temozolomide, memantine, mefloquine, and metformin as postradiation adjuvant therapy of glioblastoma (GBM).

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.tps2106

Authors: Marta Penas-Prado, Morris D. Groves, Aaron G. Mammoser, Isaac Melguizo, John Frederick De Groot, Charles A. Conrad, Ivo Tremont-Lukats, Monica Elena Loghin, Vinay K. Puduvalli, Erik P. Sulman, Kenneth R. Hess, Kenneth D. Aldape, Mark R. Gilbert, W. K. Alfred Yung

Institutions: The University of Texas MD Anderson Cancer Center, Texas Oncology, Michigan Medicine

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2602176136

Cites:

Cited by: 2

Related to: 10